Skip to main content

Domainex

  • About
    • About
    • Case Studies
    • Testimonials
    • Awards
    • Board members
    • Investors
    • Management team
    • Contact us
  • Services
    • Offerings
      • Protein Expression and Purification Services
      • X-ray crystallography
      • Assay Development
      • Biophysical Assays
      • Biochemical Assays
      • Synthetic Chemistry
      • Virtual screening
      • Fragment and Compound Screening
      • Computational Chemistry
      • Medicinal Chemistry
      • Cell Based Assays
      • ADME and Bioanalytical Sciences
      • Analytical Chemistry
    • Research Phases
      • Hit Identification
      • Hit to Lead
      • Lead Optimisation
    • Therapeutic Areas
      • Oncology
      • Immuno-Oncology
      • Cardiovascular
      • Respiratory
      • Anti-infectives
      • Inflammatory diseases
    • Target Classes
      • Kinases
      • GPCRs
      • Proteases
      • Methyltransferases
      • Ion Channels
      • Protein-Protein Interactions
    • Approaches & Techniques
      • CDH (Target Gene Fragmentation)
      • PoLiPa (Membrane Protein Solubilisation)
      • LeadBuilder
      • FragmentBuilder
      • Fragment Based Drug Discovery (FBDD)
      • Structure Based Drug Design (SBDD)
      • Differential Scanning Fluorimetry (DSF) and nanoDSF Services
      • Grating-Coupled Interferometry
      • High Throughput Screening
      • MicroScale Thermophoresis (MST) Services
      • Targeted Protein Degradation
  • Library
    • Articles
    • Brochures
    • Newsletters
    • Posters
    • Presentations
    • Publications
    • White Papers
  • News & Events
  • Careers
  • English
  • French
  • Spanish
  • German
  • Italian
  • Japanese
  • Dutch
Enquire

News & Events

Breadcrumb

  1. Home
  2. News & Events

News

33rd Medicinal Chemistry in Eastern England

17 May '22
Blog Post

Domainex appoints Dr Scott Martin as Analytical and Bioanalytical Group Leader

12 May '22
Press Release

Synthesis in Review: Useful synthetic transformations which can be applied to the synthesis of biologically relevant molecules

28 Apr '22
Blog Post

8th RSC-BMCS Fragment-based Drug Discovery

26 Apr '22
Blog Post

Domainex initiates company-wide training programmes

19 Apr '22
Blog Post

Synthesis in Review: Methods for synthesising bioisosteres to improve the properties of bioactive compounds

12 Apr '22
Blog Post
View more

Events

Sep 4 XXVll EFMC International Symposium on Medicinal Chemistry

Sep 13 17th Drug Discovery Innovation Programme

Oct 17 Discovery on Target

View more

Tweets

Tweets by Domainex_UK

Start your next project with Domainex

Contact one of our experts today
Domainex
  • About
    • About
    • Case Studies
    • Testimonials
    • Awards
    • Board members
    • Investors
    • Management team
    • Contact us
  • Services
    • Offerings
      • Protein Expression and Purification Services
      • X-ray crystallography
      • Assay Development
      • Biophysical Assays
      • Biochemical Assays
      • Synthetic Chemistry
      • Virtual screening
      • Fragment and Compound Screening
      • Computational Chemistry
      • Medicinal Chemistry
      • Cell Based Assays
      • ADME and Bioanalytical Sciences
      • Analytical Chemistry
    • Research Phases
      • Hit Identification
      • Hit to Lead
      • Lead Optimisation
    • Therapeutic Areas
      • Oncology
      • Immuno-Oncology
      • Cardiovascular
      • Respiratory
      • Anti-infectives
      • Inflammatory diseases
    • Target Classes
      • Kinases
      • GPCRs
      • Proteases
      • Methyltransferases
      • Ion Channels
      • Protein-Protein Interactions
    • Approaches & Techniques
      • CDH (Target Gene Fragmentation)
      • PoLiPa (Membrane Protein Solubilisation)
      • LeadBuilder
      • FragmentBuilder
      • Fragment Based Drug Discovery (FBDD)
      • Structure Based Drug Design (SBDD)
      • Differential Scanning Fluorimetry (DSF) and nanoDSF Services
      • Grating-Coupled Interferometry
      • High Throughput Screening
      • MicroScale Thermophoresis (MST) Services
      • Targeted Protein Degradation
  • Library
    • Articles
    • Brochures
    • Newsletters
    • Posters
    • Presentations
    • Publications
    • White Papers
  • News & Events
  • Careers
COVID-19

+44 (0) 1223 743170 enquiries@domainex.co.uk

Offerings

  • Assay Development
  • Fragment and Compound Screening
  • Cell Based Assays
  • Medicinal Chemistry
  • Synthetic Chemistry
  • Computational Chemistry
  • Analytical Chemistry
  • ADME and Bioanalytical Sciences
  • Protein Expression and Purification Services
  • X-Ray crystallography
  • Biochemical Assays
  • Biophysical Assays

Research Phases

  • Lead Optimisation
  • Hit to Lead
  • Hit Identification

Therapeutic Areas

  • Anti-infectives
  • Inflammatory diseases
  • Oncology
  • Immuno-Oncology
  • Cardiovascular
  • Respiratory Disease

Target Classes

  • Ion Channels
  • Protein-Protein Interactions
  • Kinases
  • GPCRs
  • Proteases
  • Protein Methyltransferases

Approaches & Techniques

  • Structure Based Drug Design (SBDD)
  • Ligand binding assays by Surface Plasmon Resonance (SPR) and/or Grating-Coupled Interferometry (GCI)
  • MicroScale Thermophoresis (MST) Services
  • Differential Scanning Fluorimetry (DSF) and nanoDSF Services
  • High Throughput Screening
  • Targeted Protein Degradation
  • CDH (Target Gene Fragmentation)
  • LeadBuilder – Virtual Screening
  • FragmentBuilder: Fragment-Based Drug Discovery and Design
  • Innovative Polymer Lipid Particle (PoLiPa) Technology

Domainex is a registered company (number 4336899)

Site and its contents Copyright © Domainex 2022. All rights reserved.